CD8A and neoplasm: 1) Tremelimumab in combination with tumor ablation is a potential new treatment strategy for patients with advanced BTC.2) Increased circulating activated CD8+ T cells and TCR repertoire expansion induced by tremelimumab may contribute to treatment benefit.3) This article is protected by copyright. All rights reserved.